Table 1.
Baseline demographic and clinical characteristics
| Characteristic | n (percentage where applicable) |
|---|---|
| Median age (years) | 48 (range: 16-78) |
| <50 | 60 (57.1) |
| ≥50 | 45 (42.9) |
| Gender | |
| Male | 60 (57.1) |
| Female | 45 (42.9) |
| ECOG PS | |
| 0/1 | 37 (35.3) |
| ≥2 | 68 (64.7) |
| 2 | 60 (57.1) |
| 3 | 8 (7.6) |
| Site of disease | |
| Upper 1/3 | 42 (40) |
| Middle 1/3 | 17 (16) |
| Lower 1/3 | 46 (44) |
| Histopathology | |
| PDAC | 36 (34.3) |
| MDAC | 43 (41) |
| WDAC | 24 (22.9) |
| Adenocarcinoma, NOS | 2 (1.9) |
| Mucinous histology | |
| Yes | 8 (7.6) |
| No | 97 (92.4) |
| Signet ring histology | |
| Yes | 14 (13.3) |
| No | 91 (86.7) |
| Baseline CEA status | |
| CEA>ULN | 88 (83.8) |
| CEA≤ULN | 17 (16.2) |
| Baseline obstruction requiring diversion stoma | |
| Yes | 61 (58.1) |
| No | 44 (41.9) |
| Metastatic sites of disease | |
| Liver limited | 31 (29.5) |
| Lung limited | 10 (9.5) |
| Non loco-regional nodes | 13 (12.4) |
| Peritoneal limited | 6 (5.7) |
| Others | 3 (2.9) |
| >1 site of disease | 42 (40) |
| Metastatic resectability status at baseline | |
| Potentially resectable | 38 (36.2) |
| Unresectable | 67 (63.8) |
ECOG PS=Eastern Oncology Group performance status, PDAC=Poorly differentiated adenocarcinoma, MDAC=Moderately differentiated adenocarcinoma, WDAC=Well differentiated adenocarcinoma, NOS=Not otherwise specified, ULN=Upper limit of normal, CEA=Carcinoembryonic antigen